**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 5678**

**Columns: TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (1): Hepatocellular carcinoma

**Oxidative damage in the progression of chronic liver disease to hepatocellular carcinoma: An intricate pathway**

Cardin R *et al*. Oxidative damage in chronic liver disease

Romilda Cardin, Marika Piciocchi, Marina Bortolami, Andromachi Kotsafti, Luisa Barzon, Enrico Lavezzo, Alessandro Sinigaglia, Kryssia Isabel Rodriguez-Castro, Massimo Rugge, Fabio Farinati

**Romilda Cardin, Marika Piciocchi, Marina Bortolami, Andromachi Kotsafti, Kryssia Isabel Rodriguez-Castro, Fabio Farinati,** Department of Surgery, Oncology and Gastroenterology, University of Padova, 35128 Padova, Italy

**Luisa Barzon, Enrico Lavezzo, Alessandro Sinigaglia,** Department of Molecular Medicine, University of Padova, 35128 Padova, Italy

**Massimo Rugge,** Department of Medicine, University of Padova, 35128 Padova, Italy

**Author contributions:** Cardin R, Piciocchi M, Bortolami M and Kotsafti A contributed to the conception, design and acquisition of data and approved the final version to be published; Barzon L, Lavezzo E and Sinigaglia A carried out the experiments related to miRNAs; Rodriguez-Castro K revised the manuscript and approved the final version; Rugge M analyzed and interpreted the liver pathology; Farinati F proposed the study and drafted the manuscript.

**Correspondence to: Fabio Farinati, MD, Professor**, Department of Surgery, Oncology and Gastroenterology, University of Padova,Via Giustiniani 2, 35128Padova,Italy. fabio.farinati@unipd.it

**Telephone:** +39-49-8211305 **Fax**: +39-49-8760820

**Received:** September 20, 2013 **Revised:** November 20, 2013

**Accepted:** January 6, 2014

**Published online:**

**Abstract**

The histo-pathologic and molecular mechanisms leading to initiation and progression of hepatocellular carcinoma (HCC) are still ill-defined; however, there is increasing evidence that the gradual accumulation of mutations, genetic and epigenetic changes which occur in preneoplastic hepatocytes results in the development of dysplastic foci, nodules, and finally, overt HCC. As well as many other neoplasias, liver cancer is considered an “inflammatory cancer”, arising from a context of inflammation, and characterized by inflammation-related mechanisms that favor tumor cell survival, proliferation, and invasion. Molecular mechanisms that link inflammation and neoplasia have been widely investigated, and it has been well established that inflammatory cells recruited at these sites with ongoing inflammatory activity release chemokines that enhance the production of reactive oxygen species. The latter, in turn, probably have a major pathogenic role in the continuum starting from hepatitis followed by chronic inflammation, and ultimately leading to cancer. The relationship amongst chronic liver injury, free radical production, and development of HCC is explored in the present review, particularly in the light of the complex network that involves oxidative DNA damage, cytokine synthesis, telomere dysfunction, and microRNA regulation.

©2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Reactive oxygen species; Viral hepatitis; Hepatocellular carcinoma; Telomere dysfunction; Cytokines; mitochondria; Antioxidant mechanisms; MicroRNA and circulating free DNA

**Core tip:** In this review, the relationship amongst chronic liver injury, free radical production, and development of hepatocellular carcinoma is explored. The review confirms the existence, in the intricate pathway involved in the progression of virus-related liver injury to cirrhosis and cancer, of a link between oxidative genomic and mitochondrial damage and telomere dysfunction. This link develops in the context of inflammatory response and induces a derangement of mechanisms controlling liver proliferation. In this scenario, mitochondria are emerging as a possible target for new treatments aimed at counteracting oxidative damage and disease progression to cancer, given their relevant role in inflammation and carcinogenesis.

Cardin R, Piciocchi M, Bortolami M, Kotsafti A, Barzon L, Lavezzo E, Sinigaglia A, Rodriguez-Castro KI, Rugge M, Farinati F. Oxidative damage in the progression of chronic liver disease to hepatocellular carcinoma: An intricate pathway.

**Available from:**

**DOI:**

**EPIDEMIOLOGY**

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver, the ﬁfth most common cancer in men worldwide, and the seventh most frequent in women, with over 600000-650000 new cases diagnosed annually. Hepatitis B virus (HBV) and hepatitis C virus (HCV)-related chronic liver diseases are responsible for the majority of HCC cases, making this neoplasia potentially preventable.

The distribution of HCC presents a sharp variability according to the geographic area involved. In general terms, there are three major areas with different incidence rates: Eastern Asia and sub-Saharan Africa, with incidence rates that peak at 100/100000 individuals, Mediterranean countries such as Italy, Spain, and Greece with intermediate rates (10-20 per 100000 individuals), and North and South America, with a relatively low incidence (< 5 per 100000). In regions at high incidence, the most common cause is HBV transmitted at birth, while in North America and Europe the most common etiology is HCV, with infection acquired much later in life.

Male gender is a risk factor for HCC, that is in fact more common in men than in women, partly dependent upon factors other than viral infection, such as the hormonal and immunological status, as well as alcohol consumption. The major established risk factor is cirrhosis, insofar as 80%-90% of cases of HCC occur in the setting of cirrhosis[1].

**ETIOLOGY**

A variety of factors have been associated with the development of HCC, including hepatitis viruses, heavy alcohol intake, nonalcoholic fatty liver disease (NAFLD), aflatoxin B1 (AFB1) exposure, obesity, diabetes, dietary habits, and iron accumulation[2] . The presence and importance of these factors vary according to the geographical region, thereby influencing preventive measures that may be enacted, prognosis of patients, and treatment recommendations[3]. The incidence of HCC is rising rapidly in some, but not in all, Western countries, and is declining in Europe[4] in relation to the distribution of risk factors (hepatitis C infection, alcoholism, and obesity)[5].Recent data indeed demonstrate that HCV is now declining as a risk factor for HCC[6].It is well established that both HBV and HCV cause malignant transformation and lead to HCC development through direct and indirect mechanisms. The former involve viral proteins and specific mutations induced by the integration of the virus into the host genome, which is particularly true for HBV infection. Indirect mechanisms, in contrast, imply the induction of chronic inflammation by the immune response elicited. The time course of virus-related liver damage and the development of HCC is different based on the virus considered: progression of the disease to HCC in HCV-infected patients requires nearly 10 years from the establishment of cirrhosis, and approximately 30 years from the initial exposure to the virus. On the other hand, the course of HBV infection is less predictable, and HCC may thus precede the occurrence of cirrhosis[1,7].

**INFLAMMATION AND OXIDATIVE STRESS**

In the last twenty years, the main focus of our research group has been to investigate the events related to oxidative stress occurring in the natural history of viral hepatic disease, with a particular interest in the pathways of HCC development resulting from HBV- and HCV-related damage. The relationship between chronic inflammation and the risk of cancer development is well known. Virchow established more than a century ago the link between cancer and inflammation, and a bulk of evidence from published and ongoing studies contributes to elucidating the molecular mechanisms at the basis of this process. Inflammation involves macrophages, mast cells, dendritic and natural killer cells that are recruited within damaged tissues, and which release chemical mediators such as cytokines, chemokines, and Reactive Oxygen Species (ROS)[8]. The most important ROS include free oxygen radicals like superoxide (O2•-), hydroxyl radical (OH•), nitric oxide (NO•) radicals, as well as non-radical ROS like hydrogen peroxide (H2O2), organic hydroperoxides, and hypochloride. A physiologic amount of ROS plays a key role in several cellular processes including proliferation, apoptosis, cell cycle arrest, and cell senescence. Different anti-oxidant mechanisms regulate ROS production, but when generated ROS exceed the basal amount and the cellular defenses, they can damage cell macromolecules including proteins, lipids, and nucleic acids (DNA and RNA). Under these conditions, ROS might play a major role in the genesis of different chronic diseases and, particularly, in the initiation/promotion phase of carcinogenesis. In particular, ROS may stimulate the growth of malignant cells or increase the activity of carcinogenic xenobiotics by facilitating their activation to reactive compounds. Among the many ROS produced during the inflammatory process, the most damaging is OH•, which is responsible for a number of lesions. When DNA is attacked by ROS, stable covalent bonds are produced, leading to the formation of base modifications, in­cluding the formation of thymine and thymidine glycol, 5-hydroxyl­methyluracil, and 8-hydroxydeoxyguanosine (8-OHdG). 8-OHdG, the main ROS-induced DNA adduct, generates a point mutation in the DNA daughter strands. In fact, studies using DNA templates containing 8-OHdG indicate that the adduct accumulates and causes mispairing, thus suggesting that this lesion is muta­genic and therefore potentially carcinogenic. Thus, 8-OHdG is used as a reliable marker not only of oxidative stress[9] but also of cancer risk.

Results in the literature suggest that both oxidative and nitrative DNA damage occur at the sites of carcinogenesis, regardless of the etiology of the disease. Inducible nitric oxide synthase (iNOS) produces NO through a reaction that converts arginine and oxygen into citrulline. NO is a major mediator of chronic inflammation and participates in the regulation of cell proliferation, survival, migration, angiogenesis, DNA repair, and drug resistance. Therefore, excessive amounts of reactive nitrogen species produced *via* iNOS in chronic inflammation may play an important role in tumorigenesis[10] and it has been suggested that selective targeting of iNOS may prove a useful therapeutic or chemopreventive measure[11,12].

An increased production of ROS has been documented in virus-related disease, with a strong link between HCV core protein or HBV X protein on one hand, and oxidative ‘burst’ on the other, particularly in the first phases of carcinogenesis[13]. Our own findings have suggested a progressive build-up of genomic oxidative damage which takes place not only in patients with chronic hepatitis and cirrhosis, but also in anti-HCV positive patients with persistently normal ALT levels[14]. Our data on 8-OHdG in HCV-related liver damage have been confirmed by others, such as Shimoda *et al*[15], who also reported increased levels of 8-OHdG in DNA extracted from liver tissues and leukocytes of individuals with chronic HCV-related liver disease[16,17]. New results on HBV-related liver damage have shown a delayed accumulation of oxidative DNA damage with respect to HCV patients, which significant increases only in the later stages of the disease, in association with a significant accumulation of fibrosis, and this is particularly true in livers of patients in whom cancer develops (unpublished data).

**OXIDATIVE STRESS AND DNA REPAIR ENZYME**

Like any other DNA damage, 8-OHdG undergoes a specific repair process. A human DNA glycosylase/AP lyase encoded by the *OGG1* gene removes 8-OHdG directly from DNA and suppresses its mutagenic effect. Among the multiple OGG1 isoforms, OGG1-type 1a is expressed mainly in human cells and repairs chromosomal DNA. The human *OGG1* gene maps to chromosome 3p26.2 and allelic deletions of this region frequently occur in a variety of human cancers. Inactivation of the *OGG1* gene in yeast and mice leads to high rates of spontaneous mutation in the cells. The gene is also somatically mutated in certain cancer cells, and is highly polymorphic among human populations. The repair activity of mutated and polymorphic OGG1 protein is lower than that of the wild-type OGG1 protein, and may consequently be involved in human carcinogenesis, though full agreement on the point has not been reached[18,19].

We evaluated *OGG1* gene polymorphism in HBV- and HCV-related hepatitis tissue samples. No significant difference was found between 8-OHdG levels evaluated in wild type compared with heterozygous patients, nor in HCV or HBV patients with HCC, nor in chronic hepatitis and cirrhosis, therefore downsizing the relevance of *OGG1* gene polymorphism in liver disease (unpublished data).

**OXIDATIVE STRESS AND MITOCHONDRIA**

In normal healthy cells, mitochondria are involved in several fundamental cellular processes, including cell proliferation, apoptosis, and intracellular calcium homeostasis. Mitochondrial dysfunction can affect a range of important cellular functions and can result in a variety of diseases[20] . Emerging evidence strongly supports a key role of mitochondria in carcinogenesis. In conditions of oxidative stress, the transcriptional and replication machinery of mitochondria is up-regulated, thus resulting in increased mitochondrial biogenesis *via* replication of the mitochondrial genome (mtDNA). In these damaged mitochondria, the electron transport chain may be blocked, resulting in an accumulation of ROS. As mitochondrial DNA is located close to the source of ROS production, DNA itself can become damaged, resulting in accumulation of deletions and mutations[21]**.** Increased levels of ROS also alter mitochondrial metabolism, increasing mitochondrial membrane permeability and leading to the release of pro-apoptotic factors into the cytosol. Research is now more clearly defining the molecular mechanisms and the signaling pathways involved in the process of “mitochondrial malignancy”. These pathways will become clearer as the respective roles of ROS and of cancer-related proteins such as RAS, p53 and c-myc in regulating mitochondria will be clarified[22].

**OXIDATIVE STRESS, ANTI-OXIDANT DEFENSES AND DRUGS**

Cells have developed defense mechanisms to counteract the negative effects of oxidative stress, among which redox active glutathione, thioredoxin, antioxidant enzymes (superoxide dismutase, catalase and glutathione peroxidases[23] . These aspects are particularly relevant in view of the possible application of anti-oxidants in cancer prevention. Conventional anti-oxidants show little efficacy against oxidative stress *in vivo*, probably because they are not taken up by mitochondria. Mitochondria-targeted anti-oxidants such as Vitamin K3 or Vitamin E may be used to decrease mitochondrial oxidative damage, and drugs such as mitoquinone have been developed in this regard.This novel class of compounds combines a potent anti-oxidant, such as ubiquinone, with a lipophilic cation that causes the anti-oxidant to accumulate several hundred-fold within mitochondria. Several *in vitro* and animal studies have shown that this selective accumulation renders mitoquinone more protective against ROS and cell death than untargeted anti-oxidants. The administration of the above compounds may constitute a novel approach to decreasing liver damage in chronic HCV infection.Potentially, anti-oxidants could be used in association with the standard interferon/ribavirin treatment in patients with chronic HCV-related hepatitis[24,25]. Yet very few studies have been published so far on the effects of anti-oxidants in patients with chronic HCV infection. Alpha tocopherol and fermented papaya both improved redox status in HCV-related cirrhosis, but only in the subgroup of vitamin E-deficient patients was normalization of transaminase levels obtained[26]. In another study, a tomato-based food supplement increased serum lycopene and carotenoids, and decreased serum hydroperoxides in patients with HCV infection, again with no effect on transaminases[27]. In yet another study, Viusid®, a nutritional supplement containing ascorbic acid, zinc and glycyrrhizin, of recognized anti-oxidant properties, achieved reduction of serum oxidative stress markers in patients with chronic HCV-related hepatitis; no effect on the evolution of liver damage was reported, however[28]. Finally, in another study, a combination of different anti-oxidants at the “appropriate” dose for twenty weeks achieved normalization of liver enzymes levels in 44% of treated patients, decreasing viral load in 25%[29]. Studies recently published by our group have demonstrated that coffee consumption induces a significant reduction of oxidative DNA damage, thus confirming that the protection exerted by coffee with respect to HCC is mediated by a reduced accumulation of oxidized bases, and consequently, of DNA mutations. The relevance of oxidative **stress** in carcinogenesis[30] and, particularly in patients with HCV infection[17,31] , is well known, and the association between coffee consumption and lower oxidative DNA damage has been recently observed also by Mišík *et al*[32] in healthy volunteers. The protective effect of coffee with respect to HCC may be due to the numerous antioxidant compounds contained in this beverage, among which are polyphenols, or to the induction of antioxidant enzymes. This effect is exerted even at very small doses or even when coffee is consumed for a relatively short period, as in our above quoted study. Confirming what above, long-term glycyrrhizin administration reportedly reduces HCC incidence in interferon-resistant patients with chronic HCV infection[33], as demonstrated in a cohort study, which although not randomized, included a large series of patients and produced results which are sound enough to be considered as relevant.

**OXIDATIVE STRESS, CYTOKINES AND APOPTOSIS**

As has been amply discussed herein, liver injury is associated with chronic inﬂammation; in a local inflammatory milieu, several cell types normally residing in the liver (sinusoidal, endothelial and Kupffer cells) produce immune mediators as well as cytokines and chemokines, whose receptors are located on the cell surface of hepatocytes.

These cells also express and release IL-6, an important pro-inflammatory cytokine involved in tumor cell proliferation by its role in inhibiting apoptosis through the activation of signal transducer and activator of transcription 3 (STAT3)[34]. tumor necrosis factor-α (TNF-α), a pro-inflammatory immune mediator produced by Kupffer cells and other immune cells in response to tissue injury, triggers the production of other cytokines that, in turn, recruit inﬂammatory cells, promoting ﬁbrogenesis and further activating the oxidative burst[35]. Amongst the myriad effects of TNF-α is, importantly, the activation of intracellular apoptotic and⁄or anti-apoptotic pathways. The role of TNF-α expression in HCC, however, remains controversial, with reports of expression varying from high[36] to low[37,38]. The question that ensues is henceforth to establish how persistent oxidative stress ﬁts into this scenario. TNF-α also has an important role in oxidative stress induction, causing DNA damage through the formation of 8-OHdG in primary murine hepatocytes[39]. The overproduction of oxidative species linked to the over-expression of inﬂammatory cytokines may be responsible for inhibiting the apoptotic process, probably by activating the NF-kB-dependent pathway[40]. Oxidative stress is also related to the expression of proto-oncogenes, such as c-myc, which is signiﬁcantly more expressed in cirrhotic than in non-cirrhotic tissues in our experience as well. This means that the progression of tissue damage from hepatitis to cirrhosis, and the related cell growth changes, may be to some degree mediated by c-myc[41]. For instance, recent studies have demonstrated that TGF-α⁄c-myc double transgenic mice exhibit enhanced cell proliferation and accumulate extensive oxidative DNA damage, a phenomenon that may account for an accelerated progression to cancer[42]. Recently, we sought the possible correlations between oxidative DNA damage and levels of pro-inflammatory cytokines, TGF-α and c-myc in chronic HCV-related liver damage, and a clear correlation between 8-OHdG levels and c-myc expression has been detected, confirming the relevance of oxidative DNA damage in liver carcinogenesis[17]. As far as IL-1β is concerned, recent reports have shown that higher levels of this cytokine are present in HCV-related liver disease with respect to other forms of liver damage[43] and that its polymorphisms are correlated with the risk of progression to HCC. IL-1β has been reported to trigger the inﬂammatory response cascade and to directly cause growth arrest and TNF-α expression induction[44,45]. This last effect was not conﬁrmed in our experience, however, since no correlation emerged between IL-1β and TNF-α levels in liver tissues of patients with HCV-related liver damage[46]. On the other hand, IL-1β expression was higher in the later stages of HCV-related liver disease, as already demonstrated by Gramantieri *et al*[47].

**OXIDATIVE STRESS AND EPITHELIAL-MESENCHYMAL TRANSITION**

Epithelial-mesenchymal transition (EMT) is a biologic process by which epithelial cells undergo changes that induce the development of a mesenchymal phenotype, increasing the production of extracellular matrix proteins and the resistance to apoptotic cell death. These changes are considered as a driving force also in tumor progression since they enhance the cell migratory ability and invasiveness.

Several studies demonstrated the existence of a strong correlation between ROS production and EMT, a link that involves NF-kB activation in collaboration with hypoxia-related production of HIF-1 and COX2[48].HCV and HBV infections are involved in prompting EMT in the development of HCC, a process in which the progression of malignant hepatocytes depends in part on the signaling of transforming growth factor (TGF)-β, produced by stromal cells (fibroblasts, macrophages *etc*.)[23]. TGF-β activation triggers an increase in intracellular ROS production in association with the phosphorylation of Smad2, p38 and ERK1/2[49].

Many other factors correlated with ROS production are involved in EMT, such as MAPK activation and angiotensin II, E-cadherin and α-SMA up-regulation, thus supporting a redox-mediated regulation of EMT[23].

**OXIDATIVE STRESS AND TELOMERE DYSFUNCTION**

Cells that are not able to start the process of apoptosis, in particular after DNA damage, can be more susceptible to genetic alterations and to the acquisition of immortality through the modulation of telomerase activity. Telomerase, a RNA-dependent DNA polymerase, is a complex ribonucleoprotein including two components, a catalytic subunit (TERT) and a RNA component complementary to telomeric sequences (TR). After retrotrascription of its own RNA, telomerase adds telomeric sequences to chromosomal terminal portions, thus maintaining the length of telomeres, whose main function is to stabilize the chromosomal structure, endowing this molecule with a very important role in cell proliferation, senescence, immortalization and carcinogenesis[50]. Nevertheless, telomeres shorten at each replication cycle, and lose their function after reaching a critical length (telomeric crisis). Telomere shortening may result in end-to-end fusions during the cell cycle and, consequently, somatic cells stop proliferation and enter senescence phase and apoptosis[51]. In neoplastic cells, telomeric shortening, senescence, and apoptosis are avoided by an increased telomerase function. Telomere shortening and chromosomal instability occur in the first phases of carcinogenesis, while tumor progression is linked to a telomeric preservation induced by a restarting of telomerase activity. In fact, only cells that maintain telomere length, with unlimited cell divisions and chromosomal instability, possess a higher potential of neoplastic transformation and progression to cancer. The telomeres, rich in guanines, are highly sensitive to ROS attack, in particular by hydroxyl radical. ROS interaction with telomeric sequences creates DNA adducts as 8-OHdG. Thus, oxidative stress can accelerate telomeric shortening also because, unlike in most genomic DNA, the repair mechanisms of telomeric DNA are less efficient and telomeres more easily accumulate oxidative damage. Consequently, measuring telomere length may constitute an optimal biomarker of chronic oxidative stress[52]. Only a few studies have specifically examined the relationship between telomerase activity, telomere length and the extent of oxidative stress and consequent oxidative DNA damage in hepatocarcinogenesis. Our group has demonstrated that oxidative DNA damage interferes with telomere function, thus playing a key role in hepatic carcinogenesis (unpublished data). In fact, we confirmed theshorter telomere length in both HCV- and HBV- related HCC, possibly due to the accumulation of genetic alterations and 8-OHdG during disease progression. Alterations of the promoter may be one of the factors that control the transcriptional activity of TERT. The hypermethylation of CpG islands acts as an alternative, complementary pathway to gene mutation, and is an important mechanism involved in carcinogenesis. Both HBV and HCV induce epigenetic changes in speciﬁc genes involved in DNA repair, cell cycle control, and apoptosis signaling (RASSF1A, GSTP1, CHRNA3, and DOK1) in HCC as compared to cirrhotic or normal liver tissues[53,54]. Our data confirm changes in the methylation levels of the TERT promoter gene in the terminal stages of the disease in both HBV- and HCV-related hepatitis. Further studies are needed to better understand the mechanisms regarding genetic and epigenetic changes induced by HBV and HCV in hepatocytes. The majority of the biological properties ascribed to TERT have been limited to its effects in the nuclear genome. Several data have been published, however, demonstrating that TERT is also targeted towards mitochondria, resulting in telomerase activity in this organelle. TERT can shuttle from the nucleus to mitochondria upon oxidative challenge. Nevertheless, the exact role of mitochondrial TERT remains controversial, with some authors sustaining that it exacerbates oxidative injury while others reporting a protective effect. Recent data in literature report that conditions of chronic oxidative stress may lead to the migration of TERT subunit of telomerase to the cytosol, following the phosphorylation of tyrosine 707 by the Src kinase, thus reducing nuclear activity of the enzyme[55-58]. Our group has also observed TERT subunit translocation from nucleus to mitochondria in HCC tissue samples under oxidative stress. What the function of TERT is in mitochondria remains a matter of debate, but one of the most relevant hypothesis is that it may play a role in modulating apoptosis. In fact, Haendeler *et al*[59] demonstrated than TERT interacts with mtDNA, improving the electron transport chain activity and protecting cells from ROS-induced oxidative damage. This mechanism would reduce the permeability of the mitochondrial membrane and would avoid the leakage of pro-apoptotic factors. The reduction of apoptotic signals in a context of chronic oxidative stress, genomic instability, and increased cell proliferation might be very crucial in terms of neoplastic transformation.

**OXIDATIVE STRESS AND MICRORNAS**

Recently, the important role of microRNAs (miRNAs) in the different stages of chronic liver diseases in the development of HCC of has been recognized[60]. MiRNAs are small (21–23 nucleotides long), a noncoding RNA family involved in post-transcriptional gene regulation of their target genes. In fact, miRNAs induce translational repression *via* their binding to partially complementary sequences or mRNA degradation through their binding to perfectly complementary sequences in the 3’UTR of mRNAs[61]. Each mature miRNA potentially controls many gene targets, and each mRNA is regulated by multiple miRNAs. To date, more than 17000 distinct mature miRNA sequences have been identified from over 140 species[62]. MiRNAs are now clearly identified as key mediators of the immune system development and function, in particular for activation in response to infection during both the innate and the adaptive immune responses. At the same time, miRNA dysregulation is a central event in the development of a number of cancers, as it is involved in inflammation and oncogenesis. Several miRNAs, whose expression is modulated in HCC, have been identified, again also during oxidative damage (Table 1). Our research group has recently published a significant positive correlation between miRNA-92 expression, which is already linked to hepadnavirus-associated carcinogenesis, c-myc and 8-OHdG levels in HCC tissues. Besides, our data demonstrate that miRNA-199a, miRNA-199b, miRNA-195 and miRNA-122a are strongly down-regulated in the majority (55%–70%) of HCCs, while miRNA-92 and miRNA-145 show a less marked down-regulation. In contrast, miRNA-222 is up-regulated in HCC[72].

**OXIDATIVE STRESS AND CIRCULATING FREE DNA**

As previously exposed, oxidative stress is known to cause DNA damage, and cells with the greatest DNA injury die either by necrosis or apoptosis. Oxidized DNA released from dying cells is likely the most prominent contributor to circulating cell-free DNA (cfDNA), which is a double or single stranded extracellular DNA, released by tumor apoptotic or necrotic cells and circulating in blood as a complex with histonic proteins[73]. Low levels of cfDNA can be detected as well in healthy individuals, but higher levels characterize patients with a number of diseases including cancer[74]. Our recent study has investigated the time course of cfDNA levels in patients in different stages of liver damage, from chronic hepatitis to cirrhosis and cancer. Data have shown that cfDNA is detectable in a small share of these last patients, but in a substantially similar percentage of CIRR and HCC patients. In HCC however, cfDNA levels are, on average, two times higher than in CIRR and, by choosing the right cut-off with ROC curves, the sensitivity in diagnosis is notably high. In our experience therefore, the role of the cfDNA quantitative analysis as a valuable diagnostic test is debatable, but cfDNA levels allow for patients discrimination with more advanced stages of disease, demonstrating a prognostic relevance in patients with HCC (unpublished data).

In conclusion, we confirm the existence of a link between oxidative genomic and mitochondrial damage and telomere dysfunction in the intricate pathway (Figure 1) involved in the progression of virus-related liver injury to cirrhosis and HCC. This link develops in the context of the inflammatory response and leads to a derangement of the basic mechanisms controlling liver proliferation.

Unfortunately, despite the evidence of a clear role for oxidative burst as an inducer of liver damage in patients with viral hepatitis, nor antioxidant drugs nor cocktails of vitamins or different compounds have been demonstrated to actively interfering with the development of damage. In this scenario, mitochondria are emerging as a possible target for new treatments aimed at counteracting oxidative damage and disease progression as well as cancer development, given the relevant role that these organelles play in inflammation and carcinogenesis.

**REFERENCES**

1 **Mittal S**, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. *J Clin Gastroenterol* 2013; **47 Suppl**: S2-S6 [PMID: 23632345 DOI: 10.1097/MCG.0b013e3182872f29]

2 **Aravalli RN**, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. *Hepatology* 2008; **48**: 2047-2063 [PMID: 19003900 DOI: 10.1002/hep.22580]

3 **Marrero JA**, Kudo M, Bronowicki JP. The challenge of prognosis and staging for hepatocellular carcinoma. *Oncologist* 2010; **15 Suppl 4**: 23-33 [PMID: 21115578 DOI: 10.1634/theoncologist.2010-S4-23]

4 **Bertuccio P**, Bosetti C, Levi F, Decarli A, Negri E, La Vecchia C. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. *Ann Oncol* 2013; **24**: 1667-1674 [PMID: 23378539 DOI: 10.1093/annonc/mds652]

5 **El-Serag HB**. Surveillance for hepatocellular carcinoma: long way to achieve effectiveness. *Dig Dis Sci* 2012; **57**: 3050-3051 [PMID: 23053890 DOI: 10.1007/s10620-012-2413-z]

6 **Cazzagon N**, Trevisani F, Maddalo G, Giacomin A, Vanin V, Pozzan C, Poggio PD, Rapaccini G, Nolfo AM, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Foschi FG, Cabibbo G, Felder M, Ciccarese F, Missale G, Baroni GS, Morisco F, Pecorelli A, Farinati F. Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres. *Liver Int* 2013; **33**: 1420-1427 [PMID: 23758775 DOI: 10.1111/liv.12208]

7 **Marra M**, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M, Agresti M, Caraglia M, Sperlongano P. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. *J Transl Med* 2011; **9**: 171 [PMID: 21985599 DOI: 10.1186/1479-5876-9-171]

8 **Marx J**. Cancer research. Inflammation and cancer: the link grows stronger. *Science* 2004; **306**: 966-968 [PMID: 15528423 DOI: 10.1126/science.306.5698.966]

9 **Kuchino Y**, Mori F, Kasai H, Inoue H, Iwai S, Miura K, Ohtsuka E, Nishimura S. Misreading of DNA templates containing 8-hydroxydeoxyguanosine at the modified base and at adjacent residues. *Nature* 1987; **327**: 77-79 [PMID: 3574469 DOI: 10.1038/327077a0]

10 **Sawa T**, Ohshima H. Nitrative DNA damage in inflammation and its possible role in carcinogenesis. *Nitric Oxide* 2006; **14**: 91-100 [PMID: 16099698 DOI: 10.1016/j.niox.2005.06.005]

11 **Crowell JA**, Steele VE, Sigman CC, Fay JR. Is inducible nitric oxide synthase a target for chemoprevention? *Mol Cancer Ther* 2003; **2**: 815-823 [PMID: 12939472]

12 **Hofseth LJ**. Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer. *Cancer Lett* 2008; **268**: 10-30 [PMID: 18440130 DOI: 10.1016/j.canlet.2008.03.024]

13 **Koike K**, Tsutsumi T, Fujie H, Shintani Y, Kyoji M. Molecular mechanism of viral hepatocarcinogenesis. *Oncology* 2002; **62 Suppl 1**: 29-37 [PMID: 11868782]

14 **Cardin R**, Saccoccio G, Masutti F, Bellentani S, Farinati F, Tiribelli C. DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study. *J Hepatol* 2001; **34**: 587-592 [PMID: 11394660]

15 **Shimoda R**, Nagashima M, Sakamoto M, Yamaguchi N, Hirohashi S, Yokota J, Kasai H. Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. *Cancer Res* 1994; **54**: 3171-3172 [PMID: 8205535]

16 **Farinati F**, Cardin R, Degan P, De Maria N, Floyd RA, Van Thiel DH, Naccarato R. Oxidative DNA damage in circulating leukocytes occurs as an early event in chronic HCV infection. *Free Radic Biol Med* 1999; **27**: 1284-1291 [PMID: 10641722]

17 **Farinati F**, Cardin R, Bortolami M, Burra P, Russo FP, Rugge M, Guido M, Sergio A, Naccarato R. Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. *J Viral Hepat* 2007; **14**: 821-829 [PMID: 18070284 DOI: 10.1111/j.1365-2893.2007.00878.x]

18 **Shinmura K**, Yokota J. The OGG1 gene encodes a repair enzyme for oxidatively damaged DNA and is involved in human carcinogenesis. *Antioxid Redox Signal* 2001; **3**: 597-609 [PMID: 11554447 DOI: 10.1089/15230860152542952]

19 **Ide H**, Kotera M. Human DNA glycosylases involved in the repair of oxidatively damaged DNA. *Biol Pharm Bull* 2004; **27**: 480-485 [PMID: 15056851]

20 **Michel S**, Wanet A, De Pauw A, Rommelaere G, Arnould T, Renard P. Crosstalk between mitochondrial (dys)function and mitochondrial abundance. *J Cell Physiol* 2012; **227**: 2297-2310 [PMID: 21928343 DOI: 10.1002/jcp.23021]

21 **Malik AN**, Czajka A. Is mitochondrial DNA content a potential biomarker of mitochondrial dysfunction? *Mitochondrion* 2013; **13**: 481-492 [PMID: 23085537 DOI: 10.1016/j.mito.2012.10.011]

22 **Ralph SJ**, Rodríguez-Enríquez S, Neuzil J, Saavedra E, Moreno-Sánchez R. The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy. *Mol Aspects Med* 2010; **31**: 145-170 [PMID: 20206201 DOI: 10.1016/j.mam.2010.02.008]

23 **Severi T**, van Malenstein H, Verslype C, van Pelt JF. Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. *Acta Pharmacol Sin* 2010; **31**: 1409-1420 [PMID: 20953207 DOI: 10.1038/aps.2010.142]

24 **Angelico F**, Francioso S, Del Ben M, Feole K, Carbone M, Pignatelli P, Violi F, Angelico M. Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients. *Aliment Pharmacol Ther* 2009; **30**: 444-451 [PMID: 19493257 DOI: 10.1111/j.1365-2036.2009.04055.x]

25 **Morisco F**, Verde V, Fogliano V, Ritieni A, Marmo R, De Luise G, Tuccillo C, Caporaso N. Oxidative status in chronic hepatitis C: the influence of antiviral therapy and prognostic value of serum hydroperoxide assay. *Free Radic Res* 2004; **38**: 573-580 [PMID: 15346648]

26 **Marotta F**, Yoshida C, Barreto R, Naito Y, Packer L. Oxidative-inflammatory damage in cirrhosis: effect of vitamin E and a fermented papaya preparation. *J Gastroenterol Hepatol* 2007; **22**: 697-703 [PMID: 17444858 DOI: 10.1111/j.1440-1746.2007.04937.x]

27 **Vitaglione P**, Fogliano V, Stingo S, Scalfi L, Caporaso N, Morisco F. Development of a tomato-based food for special medical purposes as therapy adjuvant for patients with HCV infection. *Eur J Clin Nutr* 2007; **61**: 906-915 [PMID: 17180159 DOI: 10.1038/sj.ejcn.1602571]

28 **Gomez EV**, Perez YM, Sanchez HV, Forment GR, Soler EA, Bertot LC, Garcia AY, del Rosario Abreu Vazquez M, Fabian LG. Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C. *World J Gastroenterol* 2010; **16**: 2638-2647 [PMID: 20518086]

29 **Melhem A**, Stern M, Shibolet O, Israeli E, Ackerman Z, Pappo O, Hemed N, Rowe M, Ohana H, Zabrecky G, Cohen R, Ilan Y. Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. *J Clin Gastroenterol* 2005; **39**: 737-742 [PMID: 16082287]

30 **Kryston TB**, Georgiev AB, Pissis P, Georgakilas AG. Role of oxidative stress and DNA damage in human carcinogenesis. *Mutat Res* 2011; **711**: 193-201 [PMID: 21216256 DOI: 10.1016/j.mrfmmm.2010.12.016]

31 **Moriya K**, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Miyazawa T, Ishibashi K, Horie T, Imai K, Todoroki T, Kimura S, Koike K. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. *Cancer Res* 2001; **61**: 4365-4370 [PMID: 11389061]

32 **Mišík M**, Hoelzl C, Wagner KH, Cavin C, Moser B, Kundi M, Simic T, Elbling L, Kager N, Ferk F, Ehrlich V, Nersesyan A, Dušinská M, Schilter B, Knasmüller S. Impact of paper filtered coffee on oxidative DNA-damage: results of a clinical trial. *Mutat Res* 2010; **692**: 42-48 [PMID: 20709087 DOI: 10.1016/j.mrfmmm.2010.08.003]

33 **Ikeda K**, Arase Y, Kobayashi M, Saitoh S, Someya T, Hosaka T, Sezaki H, Akuta N, Suzuki Y, Suzuki F, Kumada H. A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. *Dig Dis Sci* 2006; **51**: 603-609 [PMID: 16614974 DOI: 10.1007/s10620-006-3177-0]

34 **Yu H**, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. *Nat Rev Cancer* 2009; **9**: 798-809 [PMID: 19851315 DOI: 10.1038/nrc2734]

35 **Ramadori G**, Armbrust T. Cytokines in the liver. *Eur J Gastroenterol Hepatol* 2001; **13**: 777-784 [PMID: 11474306]

36 **Nakazaki H**. Preoperative and postoperative cytokines in patients with cancer. *Cancer* 1992; **70**: 709-713 [PMID: 1320454]

37 **Bortolami M**, Venturi C, Giacomelli L, Scalerta R, Bacchetti S, Marino F, Floreani A, Lise M, Naccarato R, Farinati F. Cytokine, infiltrating macrophage and T cell-mediated response to development of primary and secondary human liver cancer. *Dig Liver Dis* 2002; **34**: 794-801 [PMID: 12546515]

38 **Leonardi GC**, Candido S, Cervello M, Nicolosi D, Raiti F, Travali S, Spandidos DA, Libra M. The tumor microenvironment in hepatocellular carcinoma (review). *Int J Oncol* 2012; **40**: 1733-1747 [PMID: 22447316 DOI: 10.3892/ijo.2012.1408]

39 **Wheelhouse NM**, Chan YS, Gillies SE, Caldwell H, Ross JA, Harrison DJ, Prost S. TNF-alpha induced DNA damage in primary murine hepatocytes. *Int J Mol Med* 2003; **12**: 889-894 [PMID: 14612962]

40 **Liu TZ**, Lee KT, Chern CL, Cheng JT, Stern A, Tsai LY. Free radical-triggered hepatic injury of experimental obstructive jaundice of rats involves overproduction of proinflammatory cytokines and enhanced activation of nuclear factor kappaB. *Ann Clin Lab Sci* 2001; **31**: 383-390 [PMID: 11688850]

41 **Vermeulen K**, Berneman ZN, Van Bockstaele DR. Cell cycle and apoptosis. *Cell Prolif* 2003; **36**: 165-175 [PMID: 12814432]

42 **Hironaka K**, Factor VM, Calvisi DF, Conner EA, Thorgeirsson SS. Dysregulation of DNA repair pathways in a transforming growth factor alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis. *Lab Invest* 2003; **83**: 643-654 [PMID: 12746474]

43 **Lapiński TW**. The levels of IL-1beta, IL-4 and IL-6 in the serum and the liver tissue of chronic HCV-infected patients. *Arch Immunol Ther Exp (Warsz)* 2001; **49**: 311-316 [PMID: 11726034]

44 **Bahr MJ**, el Menuawy M, Boeker KH, Musholt PB, Manns MP, Lichtinghagen R. Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C. *Liver Int* 2003; **23**: 420-425 [PMID: 14986816]

45 **Tanaka Y**, Furuta T, Suzuki S, Orito E, Yeo AE, Hirashima N, Sugauchi F, Ueda R, Mizokami M. Impact of interleukin-1beta genetic polymorphisms on the development of hepatitis C virus-related hepatocellular carcinoma in Japan. *J Infect Dis* 2003; **187**: 1822-1825 [PMID: 12751042 DOI: 10.1086/375248]

46 **Farinati F**, Cardin R, Bortolami M, Guido M, Rugge M. Oxidative damage, pro-inflammatory cytokines, TGF-alpha and c-myc in chronic HCV-related hepatitis and cirrhosis. *World J Gastroenterol* 2006; **12**: 2065-2069 [PMID: 16610058]

47 **Gramantieri L**, Casali A, Trerè D, Gaiani S, Piscaglia F, Chieco P, Cola B, Bolondi L. Imbalance of IL-1 beta and IL-1 receptor antagonist mRNA in liver tissue from hepatitis C virus (HCV)-related chronic hepatitis. *Clin Exp Immunol* 1999; **115**: 515-520 [PMID: 10193427]

48 **Giannoni E**, Parri M, Chiarugi P. EMT and oxidative stress: a bidirectional interplay affecting tumor malignancy. *Antioxid Redox Signal* 2012; **16**: 1248-1263 [PMID: 21929373 DOI: 10.1089/ars.2011.4280]

49 **Rhyu DY**, Yang Y, Ha H, Lee GT, Song JS, Uh ST, Lee HB. Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. *J Am Soc Nephrol* 2005; **16**: 667-675 [PMID: 15677311]

50 **Artandi SE**, DePinho RA. Telomeres and telomerase in cancer. *Carcinogenesis* 2010; **31**: 9-18 [PMID: 19887512 DOI: 10.1093/carcin/bgp268]

51 **Monaghan P**. Telomeres and life histories: the long and the short of it. *Ann N Y Acad Sci* 2010; **1206**: 130-142 [PMID: 20860686 DOI: 10.1111/j.1749-6632.2010.05705.x]

52 **Houben JM**, Moonen HJ, van Schooten FJ, Hageman GJ. Telomere length assessment: biomarker of chronic oxidative stress? *Free Radic Biol Med* 2008; **44**: 235-246 [PMID: 18021748 DOI: 10.1016/j.freeradbiomed.2007.10.001]

53 **Lambert MP**, Paliwal A, Vaissière T, Chemin I, Zoulim F, Tommasino M, Hainaut P, Sylla B, Scoazec JY, Tost J, Herceg Z. Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. *J Hepatol* 2011; **54**: 705-715 [PMID: 21146512 DOI: 10.1016/j.jhep.2010.07.027]

54 **Ozen C**, Yildiz G, Dagcan AT, Cevik D, Ors A, Keles U, Topel H, Ozturk M. Genetics and epigenetics of liver cancer. *N Biotechnol* 2013; **30**: 381-384 [PMID: 23392071 DOI: 10.1016/j.nbt.2013.01.007]

55 **Chiodi I**, Mondello C. Telomere-independent functions of telomerase in nuclei, cytoplasm, and mitochondria. *Front Oncol* 2012; **2**: 133 [PMID: 23061047 DOI: 10.3389/fonc.2012.00133]

56 **Indran IR**, Hande MP, Pervaiz S. hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells. *Cancer Res* 2011; **71**: 266-276 [PMID: 21071633 DOI: 10.1158/0008-5472.CAN-10-1588]

57 **Saretzki G**. Telomerase, mitochondria and oxidative stress. *Exp Gerontol* 2009; **44**: 485-492 [PMID: 19457450 DOI: 10.1016/j.exger.2009.05.004]

58 **Sharma NK**, Reyes A, Green P, Caron MJ, Bonini MG, Gordon DM, Holt IJ, Santos JH. Human telomerase acts as a hTR-independent reverse transcriptase in mitochondria. *Nucleic Acids Res* 2012; **40**: 712-725 [PMID: 21937513 DOI: 10.1093/nar/gkr758]

59 **Haendeler J**, Dröse S, Büchner N, Jakob S, Altschmied J, Goy C, Spyridopoulos I, Zeiher AM, Brandt U, Dimmeler S. Mitochondrial telomerase reverse transcriptase binds to and protects mitochondrial DNA and function from damage. *Arterioscler Thromb Vasc Biol* 2009; **29**: 929-935 [PMID: 19265030 DOI: 10.1161/ATVBAHA.109.185546]

60 **Gailhouste L**, Gomez-Santos L, Ochiya T. Potential applications of miRNAs as diagnostic and prognostic markers in liver cancer. *Front Biosci (Landmark Ed)* 2013; **18**: 199-223 [PMID: 23276918]

61 **Ebert MS**, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. *Cell* 2012; **149**: 515-524 [PMID: 22541426 DOI: 10.1016/j.cell.2012.04.005]

62 **Kozomara A**, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. *Nucleic Acids Res* 2011; **39**: D152-D157 [PMID: 21037258 DOI: 10.1093/nar/gkq1027]

63 **Dong X**, Liu H, Chen F, Li D, Zhao Y. MiR-214 Promotes the Alcohol-Induced Oxidative Stress via Down-Regulation of Glutathione Reductase and Cytochrome P450 Oxidoreductase in Liver Cells. *Alcohol Clin Exp Res* 2013; [Epub ahead of print] [PMID: 23905773 DOI: 10.1111/acer.12209]

64 **Dai BH**, Geng L, Wang Y, Sui CJ, Xie F, Shen RX, Shen WF, Yang JM. microRNA-199a-5p protects hepatocytes from bile acid-induced sustained endoplasmic reticulum stress. *Cell Death Dis* 2013; **4**: e604 [PMID: 23598416 DOI: 10.1038/cddis.2013.134]

65 **Tsai WC**, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, Hsu MT, Hsiao M, Huang HD, Tsou AP. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. *Hepatology* 2009; **49**: 1571-1582 [PMID: 19296470 DOI: 10.1002/hep.22806]

66 **Cheung O**, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, Kellum JM, Min H, Luketic VA, Sanyal AJ. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. *Hepatology* 2008; **48**: 1810-1820 [PMID: 19030170 DOI: 10.1002/hep.22569]

67 **Hou W**, Tian Q, Steuerwald NM, Schrum LW, Bonkovsky HL. The let-7 microRNA enhances heme oxygenase-1 by suppressing Bach1 and attenuates oxidant injury in human hepatocytes. *Biochim Biophys Acta* ; **1819**: 1113-1122 [PMID: 22698995 DOI: 10.1016/j.bbagrm.2012.06.001]

68 **Boesch-Saadatmandi C**, Wagner AE, Wolffram S, Rimbach G. Effect of quercetin on inflammatory gene expression in mice liver in vivo - role of redox factor 1, miRNA-122 and miRNA-125b. *Pharmacol Res* 2012; **65**: 523-530 [PMID: 22402395 DOI: 10.1016/j.phrs.2012.02.007]

69 **Lee CG**, Kim YW, Kim EH, Meng Z, Huang W, Hwang SJ, Kim SG. Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1. *Gastroenterology* 2012; **142**: 1206-1217.e7 [PMID: 22265968 DOI: 10.1053/j.gastro.2012.01.007]

70 **Li N**, Muthusamy S, Liang R, Sarojini H, Wang E. Increased expression of miR-34a and miR-93 in rat liver during aging, and their impact on the expression of Mgst1 and Sirt1. *Mech Ageing Dev* 2011; **132**: 75-85 [PMID: 21216258 DOI: 10.1016/j.mad.2010.12.004]

71 **Hou W**, Tian Q, Zheng J, Bonkovsky HL. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. *Hepatology* 2010; **51**: 1494-1504 [PMID: 20127796 DOI: 10.1002/hep.23401]

72 **Romilda C**, Marika P, Alessandro S, Enrico L, Marina B, Andromachi K, Umberto C, Giacomo Z, Claudia M, Massimo R, Fabio F. Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma. *BMC Cancer* 2012; **12**: 177 [PMID: 22587342 DOI: 10.1186/1471-2407-12-177]

73 **Choi JJ**, Reich CF, Pisetsky DS. Release of DNA from dead and dying lymphocyte and monocyte cell lines in vitro. *Scand J Immunol* 2004; **60**: 159-166 [PMID: 15238085 DOI: 10.1111/j.0300-9475.2004.01470.x]

74 **Alix-Panabières C**, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. *Annu Rev Med* 2012; **63**: 199-215 [PMID: 22053740 DOI: 10.1146/annurev-med-062310-094219]

**P-Reviewers:** Aravalli RN, Zhang X

**S-Editor:** Zhai HH **L-Editor: E-Editor:**

**Figure 1** **Intricate pathway of molecular mechanisms involved in the progression of virus-related liver injury to cirrhosis and hepatocellular carcinoma.**

**Table 1 MicroRNAs involved in oxidative stress in different liver diseases**

|  |  |  |
| --- | --- | --- |
| **miRNA** | **Involvement in oxidative stress liver diseases** | **Ref.** |
| miR-214 | Alcohol induced liver disease | [63] |
| miR-199a-5p | Cholestatic disease | [64] |
| miR-122 | Hepatitis C virus/NASH | [65,66] |
| let-7 | HCC | [67] |
| miR-125b | Liver inflammation | [68] |
| miR-199a-3p | Mitochondrial dysfuntion | [69] |
| miR-34a/miR-93 | Liver aging (rat model)  | [70] |
| miR-196 | Hepatitis C virus | [71] |
| miR-92 | HCC | [72] |

HCC: Hepatocellular carcinoma; NASH: Non-alcoholic steatohepatitis.